Search Results - "Milán‐Segovia, R. C."

Population pharmacokinetics of levetiracetam in neonates with seizures by Lima‐Rogel, V., López‐López, E. J., Medellín‐Garibay, S. E., Gómez‐Ruiz, L. M., Romero‐Méndez, C., Milán‐Segovia, R. C., Romano‐Moreno, S.

“…Summary What is known and objective This study developed a population pharmacokinetic (PK) model of levetiracetam (LEV) for treating neonatal seizures (NS) and…”
Get full text

Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis by Milán Segovia, R. C., Domínguez Ramírez, A. M., Jung Cook, H., Magaña Aquino, M., Vigna Pérez, M., Brundage, R. C., Romano Moreno, S.

“…Summary What is known and Objective:  Rifampicin (RIF) shows wide variability in its pharmacokinetics. The purpose of this study was to develop and validate a…”
Get full text

Clinical Pharmacokinetics of Rifampin in Patients with Tuberculosis and Type 2 Diabetes Mellitus: Association with Biochemical and Immunological Parameters by Medellín-Garibay, S E, Cortez-Espinosa, N, Milán-Segovia, R C, Magaña-Aquino, M, Vargas-Morales, J M, González-Amaro, R, Portales-Pérez, D P, Romano-Moreno, S

“…Tuberculosis (TB) remains a major public health issue due to the increasing incidence of type 2 diabetes mellitus (T2DM), which exacerbates the clinical course…”
Get full text

Expression of NAT2 in immune system cells and the relation of NAT2 gene polymorphisms in the anti-tuberculosis therapy in Mexican mestizo population by Salazar-González, R., Gómez, R., Romano-Moreno, S., Medellín-Garibay, S., Núñez-Ruíz, A., Magaña-Aquino, M., Milán-Segovia, R. C., Portales-Pérez, D. P.

“…Arylamine N-acetyltransferase 2 (NAT2) metabolizes isoniazid (INH) and Single Nucleotide Polymorphisms (SNP) responsible for its activity has been reported…”
Get full text

Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation by Milán-Segovia, Domínguez-Ramírez, Jung-Cook, Magaña-Aquino, Romero-Méndez, Medellín-Garibay, Vigna-Pérez, Romano-Moreno

“…SETTING: In a previous monitoring study of rifampicin (RMP) in tuberculosis (TB) patients treated with a generic formulation of a three-drug fixed-dose…”
Get full text

Relative bioavailability of isoniazid in a fixed-dose combination product in healthy Mexican subjects by Milán-Segovia, R. C., Vigna-Pérez, M., Romero-Méndez, M. C., Medellín-Garibay, S. E., Vargas-Morales, J. M., Magaña-Aquino, M., Romano-Moreno, S.

“…SETTING: Subtherapeutic plasma isoniazid (INH) concentrations and the development of bacterial resistance may be attributed to poor quality and reduced…”
Get full text

Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis: Population pharmacokinetics of rifampicin by Milán Segovia, R. C., Domínguez Ramírez, A. M., Jung Cook, H., Magaña Aquino, M., Vigna Pérez, M., Brundage, R. C., Romano Moreno, S.

Get full text